FRAMINGHAM, Mass.--(BUSINESS WIRE)--The US Food and Drug Administration, or FDA, has accepted for review GTC Biotherapeutics, Inc.’s ("GTC", Nasdaq: GTCB) Biologics License Application, or BLA, for ATryn®. FDA’s Blood Products Advisory Committee intends to review the BLA for ATryn® during a meeting that is being planned for January 2009. Based on the achievement of these milestones, GTC has received $2 million in additional milestone payments from OVATION Pharmaceuticals, Inc.
